Evaluation of Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Brimonidine-Tartrate/Ketotifen-Fumarate (Primary)
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Bausch & Lomb
Most Recent Events
- 31 Aug 2023 Status changed from recruiting to completed.
- 23 May 2023 Planned End Date changed from 28 Aug 2023 to 7 Sep 2023.
- 23 May 2023 Planned primary completion date changed from 28 Aug 2023 to 7 Sep 2023.